INDUSTRY-SPONSORED DEVICE-SPECIFIC BIOMATERIALS ADVISORY PANELS PROPOSED BY FDA SCIENCE BOARD MEMBER; AGENCY CITES CONFLICT-OF-INTEREST CONCERNS
This article was originally published in The Gray Sheet
Executive Summary
Manufacturers of devices incorporating new biomaterials should be able to convene ad hoc advisory panels to help FDA address regulatory issues unique to the materials, FDA Science Board member Pedro Cuatrecasas, MD, president of pharmaceutical research at Parke-Davis, proposed at the board's meeting Nov. 6 in Arlington, Virginia.